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Naimark-Innovationin Biotechnology

introduction of hybrid products based on convergence of technologies
(nanotechnology and biotechnology) may raise new issues.
Our study involving a major field of innovation (gene technology), an important sector of society (health) and a key modality of social control (IP
regime) illustrates that the processes involved in innovation do not incur in a
vacuum. They are imbedded in a constellation of social, ethical, economic
and legal frameworks that vary from country to country and determine how
the balance between the benefits of innovation and its social cost is struck.
Although discussions about innovation tend to focus heavily if not exclusively on technological innovation, it is important to keep in mind that social
innovation is also critical in improving health status - not only in its own
right but also in its interaction with technological innovations. The particular
challenges associated with biotechnological health innovations are part of the
much larger overarching challenge of how to create the capacity to adopt
beneficial innovations in already heavily burdened health care systems.
Meeting this challenge fully will require more than refinements of an IP regime. It is also likely to require new institutional mechanisms and perhaps
new organizations - but that is a topic for another occasion.
Countries facing these challenges have much to learn from each other and
much to gain through active bilateral and multilateral endeavours. I am grateful to the organizers of this conference for the opportunity to participate in
the bilateral enterprise this conference represents.
DISCUSSION FOLLOWING THE REMARKS OF DR. ARNOLD
NAIMARK
MR. NARD: Given that Dr. Naimark is a panel of one, maybe I could exercise the moderator's prerogative to say a few things before we open it up.
Someone like myself who focuses much of his professional time on patent
law, there is a wonderful comparative advantage between us. You bring the
medicine and the science and a healthy dose of the legal stuff, I must say,
where my relative ignorance of molecular biology will probably manifest
itself in the next 25 minutes.
But I can bring some of the patent law to it. Let me say this: I think it is
important to distinguish between pharmaceuticals and biotechnology. And I
think in the patent debate that when it comes to the end product in the pharmaceutical industry, most all policy makers would agree that patent law has a
very strong role to play.
In biotechnology, where you are not dealing with small molecule chemistry, you have so many research tools and upstream research that we really
don't know what's going to happen with them, but we know they have some
use.
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And so if you look at it sort of as a developmental system where you have
upstream research on one hand and on downstream you have the product
itself, that you could go to your local pharmacy and your doctor could write a
prescription, the question is: Where on this spectrum does patent law fit in?
Everyone agrees it fits in down here. Where the debate is: What is patent
law's role upstream or midstream? So what you have nicely demonstrated
when we are talking about genes and proteins there is a controversy there
because if you interject exclusive rights upstream, then you create higher
transaction costs.
Can we rely on patents to license these products efficiently to get downstream in an optimal way? So that is much of the debate. So when you talk
about research exemptions and things of that nature, that's really what we are
talking about.
You can talk about it downstream as making the end product, such as antiviral and AIDS medicines, accessible, but that's not really what a debate is
in terms of IP service. That's more of a public international debate.
So with that in mind, let's have some questions.
Henry?
DR. KING: Yeah. I had a question: Dr. Naimark, the Government helps
finance this research... who determines the price for commercialization of
this very important research? Is it the Government or the private party, or
how do they work it?
Is it the Government or the private party, or how do they work it?
DR. NAIMARK: Who determines the amount that was invested in the research by government or how it should be valued in pricing the ultimate
product or process?
DR. KING: How it should be valued.
MR. NARD: What the consumer will pay for it.
DR. NAIMARK: By and large, the private sector should determine that.
DR. KING: Even though the Government finances it?
DR. NAIMARK: Yes, even though the government may have financed
the research. There may be circumstances, unrelated to the issue of who financed the research, where governments may be prompted to intervene in the
pricing of novel patented products. In Canada, for example, public concern
about drug prices led the Government to introduce compulsory licensing of
patented drugs in order to stimulate competition as a means to control price.
When compulsory licensing was removed from Canada's Patent Act in
order to meet NAFTA requirements, the Canadian government, responding
to public pressure to control prices, introduced a mechanism, the Patented
Medicines Prices Review Board. The Board has the authority to monitor
prices and set them at an acceptable level within the range of prices being
charged internationally using data from a reference group of six or seven
industrialized countries.
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This mechanism doesn't help in dealing with the prices of increasing
numbers of new and very expensive drugs coming onto the market or which
international pricing norms are not available.
To illustrate, I sit on a cancer agency board. Our drugs budget will increase by 60 percent this year to cover just five new cancer drugs. Dealing
with the cost impact of this trend for both public and private providers is a
huge challenge in both the United States and Canada. Sooner or later, there
will have to be some serious discussion between the payers, both public and
private, consumers and healthcare providers to determine how best to deal
with this contentious issue.
MR. NARD: If I may add, in the United States, the legislation referred to
is the Bayh-Dole Act, which was passed in the 1980s, allows research universities like Case and nonprofits to keep or have patent rights in federally
funded research. So your question implies sort of a double taxation.
So we pay for it to research with our tax dollars, and then we are going to
grant Case, let's say, a patent on research that comes out of the medical
school. Should the Government intervene and set those prices? The answer
so far has been no.
Let the market take care of itself, and the spillovers from the legislation
are okay because we are going to have startup biotech companies create an
increase in the economy as a whole, and consumer welfare would be enhanced, and the evidence for that certainly in some parts of this country have
been pretty good. While it has worked [in some parts of the country]; in other
parts it has not worked so well.
Next question.
DR. BARBER: If I understood you correctly, you said one of the requirements of patenting in this sort of area would be the identification of an
area of application or use. When you are patenting, is there any requirement
for that idea to have already got some sense of safety and efficacy, or is it
fairly open?
DR. NAIMARK: Not necessarily safety because in the case of products
that might flow from the patent that impact health or safety, they have to go
through regulatory approvals, clinical trials, for example. So you might get a
patent on a molecule.
You might identify the kinds of uses to which that molecule might be put
for diagnosis or therapy, but you do not at the stage of patenting have to do
any of the testing of its ultimate safety and so on. So that comes later in the
regulatory process.
And it is that later phase that, of course, distinguishes the impact of patenting and licensing on ultimate costs and prices.
So most of the cost comes at the second phase, namely, meeting all the
regulatory requirements. And you have to, therefore, distinguish between
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different kinds of biotech knowledge-based inventions, things that are subject
to rigorous and extensive regulatory requirements and high costs.
Therefore, you need long periods of patent protection versus things like
genetic tests or some other things where you do not have to meet the same
costs or regulatory requirements, and there the question comes up: Does a
one-size-fit-all patent term make sense in that kind of environment?
MR. NARD: Anything else?
MR. CRANE: Can you get this report on the web site?
DR. NAIMARK: The paper?
MR. CRANE: The paper.
DR. NAIMARK: Yeah. It needs a bit of editing, but I will send it by email to someone at the Institute, and they can get it up.
I arrived from Europe, and I didn't have time to pick up all my bits and
pieces before getting here.
MR. NARD: Thanks, Arnold.
(Session concluded.)

